| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/27/2011 | US20110020343 Auristatin drug linker conjugates |
| 01/27/2011 | US20110020341 Novel multidrug resistance-associated polypeptide |
| 01/27/2011 | US20110020340 Antibody-light fusion products for cancer therapeutics |
| 01/27/2011 | US20110020338 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes |
| 01/27/2011 | US20110020337 Methods for treating conditions associated with masp-2 dependent complement activation |
| 01/27/2011 | US20110020335 Treatment of Cancers Expressing p95 ErbB2 |
| 01/27/2011 | US20110020334 Methods for treating and preventing brain tumors based on bone morphogenetic proteins |
| 01/27/2011 | US20110020332 Prevention of tumors with monoclonal antibodies against neu |
| 01/27/2011 | US20110020327 Purification of proteins |
| 01/27/2011 | US20110020321 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/27/2011 | US20110020317 Breast tumour grading |
| 01/27/2011 | US20110020316 Composition and method to alleviate joint pain |
| 01/27/2011 | US20110020315 Treatment of inflammatory illnesses with ace2 |
| 01/27/2011 | US20110020314 Identifying haematopoietic stem cells based on cell surface markers |
| 01/27/2011 | US20110020313 Method of using and establishing an absorption rate level and a neuron firing level |
| 01/27/2011 | US20110020312 Methods for treatment of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| 01/27/2011 | US20110020311 Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy |
| 01/27/2011 | US20110020301 Use of s-adenosylmethionine (sam) and superoxide dismutase (sod) for the preparation of medicaments for the treatment of alzheimer's disease |
| 01/27/2011 | US20110020298 Collagen-binding synthetic peptidoglycans, preparation, and methods of use |
| 01/27/2011 | US20110020295 Pre-transplant accommodated organs resistant to anti-donor immunity |
| 01/27/2011 | US20110020280 Pharmaceutical composition for transnasal administration |
| 01/27/2011 | US20110020279 Rabies cure |
| 01/27/2011 | US20110020278 Inhibitors of flaviviridae viruses |
| 01/27/2011 | US20110020277 Dioxolane and Dioxolanone Fused Indolobenzadiazepine HCV NS5B Inhibitors |
| 01/27/2011 | US20110020276 Pyrrolidine Fused Indolobenzadiazepine HCV NS5B Inhibitors |
| 01/27/2011 | US20110020275 Compounds for the Treatment of Hepatitis C |
| 01/27/2011 | US20110020274 Mobilization of hematopoietic stem cells |
| 01/27/2011 | US20110020273 Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| 01/27/2011 | US20110020272 Combination therapy for treating hepatitis viral infection |
| 01/27/2011 | US20110020271 Elastin for soft tissue augmentation |
| 01/27/2011 | US20110020270 Treatment and prophylaxis |
| 01/27/2011 | US20110020269 Methods and compositions for modifying t cell immune responses and inflammation |
| 01/27/2011 | US20110020268 Agent comprising g-csf for treatment of traumatic peripheral nerve injury and method for treating traumatic peripheral nerve injury with the same |
| 01/27/2011 | US20110020267 Tweak receptor |
| 01/27/2011 | US20110020266 G-CSF Conjugates |
| 01/27/2011 | US20110020234 Rna interference mediating small rna molecules |
| 01/27/2011 | US20110020232 Cancer treatment with gama-secretase inhibitors |
| 01/27/2011 | US20110020229 Multi-Component Biological Transport Systems |
| 01/27/2011 | US20110020227 Polysaccharide-containing block copolmer particles and uses thereof |
| 01/27/2011 | US20110020226 Particle structures comprising sterols and saponins |
| 01/27/2011 | US20110020219 Anti-human tenascin monoclonal antibody |
| 01/27/2011 | US20110020216 Scaffolds for cell collection or elimination |
| 01/27/2011 | US20110018866 Structure of the farnesoid x receptor ligand binding domain and methods of use therefor |
| 01/27/2011 | DE102009034132A1 Plasmaadaptierte und balancierte Gelatinelösung Plasma-adapted and balanced gelatin solution |
| 01/27/2011 | DE102009034131A1 Composition, useful e.g. as volume substitute, and for prophylaxis and therapy of reperfusion syndrome and hypovolemia, comprises an aqueous composition of inosine and a hydrocolloid including hydroxyethyl starch, gelatin and/or albumin |
| 01/27/2011 | DE102009028015A1 Use of composition comprising proteasome inhibitor, nucleoside analog and interferon for producing an agent for treating hepatitis-C infection, and for treating against interferon and nucleoside analog resistant hepatitis-C virus infection |
| 01/27/2011 | CA2768810A1 Skin external-preparation composition |
| 01/27/2011 | CA2768621A1 Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 |
| 01/27/2011 | CA2768471A1 Methods of attenuating the loss of functional status |
| 01/27/2011 | CA2768386A1 Compounds which inhibit muscle contraction |
| 01/27/2011 | CA2768360A1 Polypeptides selective for .alpha.v.beta.3 integrin conjugated with a variant of human serum albumin (hsa) and pharmaceutical uses thereof |
| 01/27/2011 | CA2768206A1 Compositions and methods of use for post-radiation protection |
| 01/27/2011 | CA2768042A1 Raf dimers and uses thereof |
| 01/26/2011 | EP2278013A1 Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/26/2011 | EP2278011A2 Neisseria meningitidis antigens |
| 01/26/2011 | EP2278010A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278009A1 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278008A2 Streptococcus pneumoniae proteins and nucleic acids |
| 01/26/2011 | EP2278007A1 Conserved neisserial antigens |
| 01/26/2011 | EP2278006A2 Neisserial antigens |
| 01/26/2011 | EP2278004A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 01/26/2011 | EP2278002A1 Processes for the manufacture of sterilized pancreatin powder |
| 01/26/2011 | EP2277998A1 Urate oxidase |
| 01/26/2011 | EP2277920A2 Inhibitors of complement activation |
| 01/26/2011 | EP2277919A1 Treatment with anti-ERBB2 antibodies |
| 01/26/2011 | EP2277917A2 B7-H3L cell surface target and a family of antibodies recognizing that target |
| 01/26/2011 | EP2277911A1 Treatment of viral infections Apo E |
| 01/26/2011 | EP2277910A1 Albumin fusion proteins |
| 01/26/2011 | EP2277909A1 Glucagon-like peptide-2 derivatives and their therapeutic use |
| 01/26/2011 | EP2277908A2 IL-17A/F heterologous polypeptides, antibodies and therapeutic uses thereof |
| 01/26/2011 | EP2277907A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277906A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277905A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277904A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277903A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277902A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277901A2 Differential in tumour gene products and use of same |
| 01/26/2011 | EP2277900A1 Metastin derivative and use thereof |
| 01/26/2011 | EP2277899A2 Antimicrobial peptides |
| 01/26/2011 | EP2277897A1 Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 01/26/2011 | EP2277893A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/26/2011 | EP2277892A2 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 01/26/2011 | EP2277891A1 CRYSTAL STRUCTURE OF THE INFLUENZA VIRUS POLYMERASE PAc-PB1n COMPLEX AND USES THEREOF |
| 01/26/2011 | EP2277889A2 Fusion proteins of albumin and interferon beta |
| 01/26/2011 | EP2277888A2 Fusion proteins of albumin and erythropoietin |
| 01/26/2011 | EP2277887A2 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
| 01/26/2011 | EP2277594A2 Lysis / resealing process and device for incorporating an active ingredient in erythrocytes |
| 01/26/2011 | EP2277552A1 Mnk kinase proteins and diabetes |
| 01/26/2011 | EP2277531A1 Treatment of cns damage |
| 01/26/2011 | EP2277530A1 Glucagon-like peptide-2 and its therapeutic use |
| 01/26/2011 | EP2277529A1 Therapeutical application of SCF |
| 01/26/2011 | EP2277528A2 Use of VEGF and homologues to treat neuron disorders |
| 01/26/2011 | EP2277527A2 Peptide YY analogs |
| 01/26/2011 | EP2277522A2 Methods for increasing or decreasing bone density and identifying molecules |
| 01/26/2011 | EP2277521A1 Tamper-resitant oral opioid agonist formulations |
| 01/26/2011 | EP2277506A1 Non-polar buccal spray of a sedative |
| 01/26/2011 | EP2277394A1 Nutritional composition for the treatment of pressure ulcers |
| 01/26/2011 | EP2276778A1 Neurotrophic factor manf and uses thereof |
| 01/26/2011 | EP2276725A1 New ruthenium complexes as catalysts for metathesis reactions |
| 01/26/2011 | EP2276505A1 Use of a substance for manufacturing of a medicament for treatment of common cold |